论文部分内容阅读
目的探讨美托洛尔对慢性阻塞性肺疾病(慢阻肺)肺源性心脏病(肺心病)心力衰竭(心衰)患者肺动脉收缩压(PASP)、右心室舒张期内径(RV)的影响。方法 98例慢阻肺肺心病心衰患者,随机分为对照组(48例)与观察组(50例)。对照组患者实施常规治疗;在常规治疗基础上,对观察组患者实施美托洛尔治疗。比较两组患者治疗效果。结果观察组患者PASP、RV水平均显著低于对照组患者,治疗总有效率高于对照组,差异均有统计学意义(P<0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论美托洛尔能够有效降低慢阻肺肺心病心衰患者PASP、RV,同时显著提高对患者治疗的总有效率,有效改善患者的血气分析和超声心动指标,且不会增加患者的不良反应,值得推广。
Objective To investigate the effects of metoprolol on pulmonary artery systolic pressure (PASP) and right ventricular diastolic diameter (RV) in patients with chronic obstructive pulmonary disease (COPD) complicated with heart failure (pulmonary heart disease) . Methods A total of 98 COPD patients with heart failure were randomly divided into control group (48 cases) and observation group (50 cases). Patients in the control group underwent routine treatment. Metoprolol was administered to the observation group on the basis of routine treatment. Compare the treatment effect of two groups of patients. Results The PASP and RV levels in the observation group were significantly lower than those in the control group, and the total effective rate was higher than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Metoprolol can effectively reduce the PASP and RV in COPD patients with heart failure, and at the same time, it can significantly improve the total effective rate of patients ’treatment, effectively improve the blood gas analysis and echocardiography, and can not increase the patients’ adverse reactions , Worth promoting.